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TGF-b/SMAD signaling has long been known to exhibit a dual role in cancer, questioning what determines
its context-dependent functions. In this issue of Cancer Cell, Xu and colleagues describe a critical role of
the adaptor protein 14-3-3z in modulating SMAD activities by changing its interaction partners during breast
cancer progression.Transforming growth factor-b (TGF-b)
was initially discovered by its ability
to stimulate immortalized fibroblasts to
grow in soft agar, a phenotype associated
with expressing cancer-causing genes.
Subsequently, it became clear that the
‘‘transforming activity’’ of TGF-b is revers-
ible and can have potent cytostatic ef-
fects on normal epithelial cells. TGF-b is
now well known for its dual effects in can-
cer progression; while TGF-b can have
suppressive effects on normal and pre-
malignant cells, more advanced cancer
cells—frequently exposed to high levels
of TGF-b produced by themselves or the
stroma—are not only resistant to its cyto-
static effects but also stimulated in their
invasive and metastatic behavior. TGF-b
can do this directly by facilitating epithelial
tomesenchymal transition (EMT) and indi-
rectly by acting on its surrounding stroma,
promoting angiogenesis and immune
evasion (Akhurst and Derynck, 2001).
TGF-b signals via cell surface TGF-b
type I and type II serine threonine kinase
receptors and intracellular SMAD effector
proteins. Upon TGF-b receptor activation,
SMAD2 and SMAD3 become phosphory-
lated and form heteromeric complexes
with SMAD4. These SMAD complexes
can accumulate in the nucleus, where
they act as transcriptional regulators.
Because SMAD2 does not interact with
DNA and the affinity of SMAD3 and
SMAD4 for DNA is weak, there is a need
for SMADs to partner with other DNAbind-
ing transcription factors. The repertoire of
SMAD interaction partners is large and
diverse, providing a basis for multi-func-
tionality of TGF-b and its context-depen-
dent effects (Massague´, 2012). TGF-b
receptors and SMADs are mutated in
certain cancers. Inactivation of tumor sup-pressor genes, activation of proto-onco-
genes, and microenvironmental changes
can change the tumor suppressive and
the tumor promoting activity of the TGF-b
receptor/SMAD pathway.
Most cancer patients die of metastasis
and, because TGF-b is a strong driver of
this process, TGF-b pathway inhibiting
agents have been developed and tested
in clinical trials. However, these com-
pounds inhibit all TGF-b responses and
may elicit unwanted effects. Careful se-
lection of patients is warranted and
proper biomarkers are needed to select
those patients that will benefit from such
systemic TGF-b-targeted therapy. A bet-
ter understanding of the molecular mech-
anisms underlying the contextual effects
of TGF-b in cancer may allow develop-
ment of therapeutics selectively inhibiting
its pro-oncogenic effects. Previously,
Yu and colleagues provided some clues
on these mechanisms by demonstrating
that the phosphoserine/phosphothreo-
nine-binding protein 14-3-3z, which is
overexpressed in more than 40% of
breast cancers, can potentiate TGF-b/
SMAD signaling during EMT and breast
tumor progression (Lu et al., 2009). 14-3-
3z and the tyrosine kinase receptor
ErbB2 were found to cooperate in driving
non-invasive ductal carcinoma in situ
(DCIS) progression to invasive breast
ductal carcinoma (IDC). Breast tumors
expressing both ErbB2 and 14-3-3z have
a higher incidence of metastasis than
those expressing only one of them (Lu
et al., 2009). In addition, they found 14-
3-3z downregulated the cell cycle inhibi-
tor p27 and activated phosphoinositide
3-kinase, thereby promoting cancer cell
proliferation and survival (Rehman et al.,
2014 and references therein).Cancer Cell 27In this issue of Cancer Cell, Xu et al.
(2015) now examine the role of 14-3-3z
during different stages of breast cancer
progression. They first found that 14-3-
3z attenuated TGF-b-induced growth in-
hibition in immortalized non-transformed
human mammary epithelial cells by inhib-
iting the induction of cyclin-dependent
kinase inhibitor p21, a critical determinant
for the growth inhibitory effects of TGF-b.
Further experimentation revealed that 14-
3-3z downregulated 14-3-3s. 1433s
is a tumor suppressor in ErbB2-mediated
tumor progression (Ling et al., 2012) and
its expression decreases during breast
cancer progression due to promotor
methylation and/or allelic loss. Xu et al.
(2015) discovered yet another mechanism
by which 14-3-3s levels are decreased.
The Yes-associated protein 1 (YAP1)
was found to be a critical transactivator
for 1433s expression in the immortal-
ized mammary epithelial cells examined,
and its phosphorylated form was seques-
tered in the cytoplasm by 14-3-3z. 14-3-
3s is known to stabilize p53 by confining
its E3 ubiquitin ligase MDM2 in the cyto-
plasm (Lee and Lozano, 2006). p53 is a
critical SMAD partner in TGF-b-induced
p21 expression (Cordenonsi et al., 2003),
and the decrease in p53 protein induced
by 14-3-3z abrogated the TGF-b-induced
cytostatic response (Figure 1A). Because
the pre-malignant cell lines used are
already immortal, it remains to be es-
tablished whether a 14-3-3z-mediated
decrease in p53 and p21 also blocks the
tumor-suppressive TGF-b functions in
primary breast epithelial cells.
Next, Xu et al. (2015) investigated the
effect of depletion of 14-3-3z in highly
metastatic breast cancer cells. Tran-
scriptome analyses showed that the, February 9, 2015 ª2015 Elsevier Inc. 151
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Figure 1. 14-3-3z Abrogates TGF-b/SMAD-Induced Growth Inhibition and Promotes Breast Cancer Metastasis
(A) 14-3-3z inhibits TGF-b/SMAD-induced growth inhibition by repressing YAP-induced 14-3-3s expression. TGF-b receptor activation induces the formation of
SMAD complexes, which can partner with p53 to activate p21 expression to inhibit cell cycle progression. p53 protein can be degraded by the E3 ubiquitin ligase
MDM2, a process that is inhibited by 14-3-3s. YAP is a transcriptional activator of 14-4-3s. YAP can be sequestered in the cytoplasm by 14-3-3z and thereby
interferes with 14-3-3s expression.
(B) 14-3-3z promotes breast cancer metastasis by stabilizing GLI2. TGF-b-induced SMAD complexes interact with GLI2 to stimulate the expression of PTHrP.
The E3 ligase bTrCP interacts with and mediates the degradation of GLI2. 14-3-3z can displace bTrCP from GLI2.
(C) Schematic representation of progressive stages in breast cancer. On the right side, relative levels of 14-3-3z, 14-3-3s, YAP1, GLI2, phosphoSMAD2/3
(pSMAD2/3), p21, and PTHrP are indicated.
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associated with TGF-b regulated genes
induced in bone metastasis. Consistent
with this notion, knockdown of 14-3-
3z potently inhibited bone metastasis
induced by these aggressive breast can-
cer cells. In co-culture experiments of
breast cancer cells, pre-osteoblasts, and
osteoblasts, 14-3-3z was found to pro-
mote TGF-b-induced breast cancer cell
proliferation and osteoclast maturation.
Parathyroid hormone related protein
(PTHrP), a previously identified key deter-
minant of TGF-b-induced bone metas-
tasis of breast cancer (Johnson et al.,
2011), was identified as a key factor
induced by 14-3-3z. 14-3-3z was found
to increase GLI2 expression by stabilizing
GLI2 protein. GLI2 is a SMAD partner in152 Cancer Cell 27, February 9, 2015 ª2015TGF-b-induced PTHrP expression. GLI2
was previously found to interact with
14-3-3 in a phosphoserine-dependent
manner (Asaoka et al., 2010). Xu et al.
(2015) confirmed this interaction and
found that the interaction with 14-3-3z is
mutually exclusive with binding of GLI2
to its E3 ubiquitin ligase bTrCP, thereby
preventing GLI2 ubiquitination and pro-
teosomal degradation (Figure 1B).
Finally, Xu et al. (2015) investigated the
expression of 14-3-3z in relation to other
signaling components in clinical samples
of atypical ductal hyperplasia (ADH),
DCIS, IDC, and normal breast tissue.
Consistent with their in vitro and preclini-
cal in vivo animal models, 14-3-3z expres-
sion was found to positively correlate with
GLI2 and inversely correlate with (nuclear)Elsevier Inc.YAP, 14-3-3s, and p21 expression
(Figure 1C). 14-3-3z levels also correlated
with phosphoSMAD2/3 levels. In the pre-
sent study, no effects of 14-3-3z on TGF-b
receptor-induced SMAD2 phosphoryla-
tion were detected in the cell lines exam-
ined, but, previously, the group found
that by interacting with TGF-b type I re-
ceptor, 14-3-3z could stabilize this recep-
tor and thereby promote TGF-b/SMAD
signaling (Lu et al., 2009). In breast and
other cancers, the 14-3-3z gene is ampli-
fied and/or overexpressed, and this was
found to be associated with cancer recur-
rence, increased incidence of metastasis,
and resistance to certain chemotherapies
(Xu et al., 2015 and references therein).
The finding that 14-3-3z redirects TGF-b
signaling toward metastasis will spark
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use as a prognostic biomarker to stratify
patients. Tumors with high 14-3-3z may
have an active TGF-b-induced pro-tumor-
igenic response, and patients carrying
these tumors may benefit from TGF-b tar-
geted therapy. Moreover, 14-3-3z could
be explored as a therapeutic target to
specifically interfere with pathogenic ef-
fects of TGF-b. Although protein-protein
interactions are challenging to target,
several compounds that interfere with
14-3-3z signaling have been described,
but, so far, are not so potent and selec-
tive. With 14-3-3z docking with b-catenin,
GLI2, and YAP1, the downstream effec-
tors of the Wnt, Hedgehog, and Hippo
signaling pathways, respectively, andSMAD interactors, 14-3-3z may serve as
a critical integrator of signaling crosstalk
with the TGF-b/SMAD pathway.REFERENCES
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Bonemetastasis often emerges long after the initial dissemination of cancer cells. In this issue ofCancer Cell,
Wang and colleagues demonstrate that disseminated breast cancer cells engage osteogenic niches in the
bone through heterotypic adherins junctions. This interaction activates mTOR signaling in cancer cells and
supports their expansion to micrometastases.Bone metastasis is a frequent and devas-
tating complication among late-stage
breast cancer patients. These lesions are
usually osteolytic in nature,with excessive
osteoclast activities resulting in bone loss,
pathological fracture, and associated
morbidities (Weilbaecher et al., 2011).
Therefore, much of the research on bone
metastasis has focused on the molecular
crosstalk between tumor cells and bone
stroma that drives the hyperactivation of
osteoclasts. Osteoclast-targeting agents
such as bisphosphonates and the RANKL
neutralizing antibody denosumab have
been approved for clinical use to alleviate
bone metastasis-associated symptoms.
Unfortunately, these treatments are insuf-
ficient to reduce metastatic tumor burden
or improve patient survival, highlightingthe need to develop new strategies to pre-
vent or reduce bone metastasis.
Disseminated tumor cells (DTCs) are
frequently detected in the bone marrow
of early-stage breast cancer patients
without overt bone metastasis (Kang and
Pantel, 2013). Curiously, a long latency
period often exists between the initial
diagnosis and treatment of the primary
tumor and the clinical detection of overt
bone metastasis, especially among pa-
tients with estrogen receptor (ER) positive
breast cancer. These findings indicate
a crucial, and yet untapped, therapeutic
window to eliminate the potential seeds
of bone metastasis at the asymptomatic
stage by preventing DTCs from progress-
ing further. Recent studies have begun to
shed light on some of the early events dur-ing bone colonization. For example, Src
activation has been associated with late-
onset bone metastasis of breast cancer
by promoting the survival and outgrowth
of tumor cells (Zhang et al., 2009), while
VCAM1 promotes osteolytic expansion
of indolent bone micrometastasis by re-
cruiting osteoclasts (Lu et al., 2011). Pros-
tate cancer DTCs have been shown to
compete with hematopoietic stem cells
(HSCs) for occupancy in bone niches
(Shiozawa et al., 2011). However, the
cellular composition of the bone stromal
environment that provides a nurturing
niche for DTCs upon their arrival remains
unclear. In this issue of Cancer Cell,
Wang et al. (2015) used a new mouse
model of early bone metastasis, coupled
with in-depth mechanistic studies and, February 9, 2015 ª2015 Elsevier Inc. 153
